Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Lilly requests EMA to rexamine Alzheimer's drug recommendation
10:16am, Friday, 25'th Apr 2025
Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
12:40pm, Thursday, 24'th Apr 2025
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Thursday, 24'th Apr 2025
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
09:53am, Wednesday, 23'rd Apr 2025
Eli Lilly (LLY 0.73%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterl
Direxion's Eli Lilly-Focused Bull And Bear Funds Offer Speculative Alternatives
08:05am, Wednesday, 23'rd Apr 2025
Amid a challenging political and economic environment, pharmaceutical giant Eli Lilly and Company LLY may offer a potential haven in the storm. Fundamentally, the healthcare sector is generally resili
Eli Lilly Nails Oral GLP-1 Trial—Here's What It Means for LLY
07:33am, Wednesday, 23'rd Apr 2025
The world's largest pharmaceutical stock, Eli Lilly and Company NYSE: LLY, is back in the green in 2025 as of the Apr. 21 close. Shares were down moderately in 2025 through mid-April.
Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.
06:55am, Wednesday, 23'rd Apr 2025
Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (LLY 1.21%) stock cut his price target on the pharmaceutical giant. Even though that redu
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
06:30am, Wednesday, 23'rd Apr 2025
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of tirzepatide, the active ingredient in Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro. Lilly claims Mochi
Lilly sues four compounders over copies of weight-loss drugs
05:15am, Wednesday, 23'rd Apr 2025
Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss
Is Eli Lilly Stock a Buy?
05:07am, Wednesday, 23'rd Apr 2025
Type 2 diabetes and obesity have become an increasing global healthcare problem, reaching near crisis proportions in the United States. The arrival of GLP-1 agonists, drugs that mimic hormones to slow
Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note
06:50pm, Tuesday, 22'nd Apr 2025
Eli Lilly (LLY) closed at $827.54 in the latest trading session, marking a +1.16% move from the prior day.
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
11:13am, Tuesday, 22'nd Apr 2025
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
09:53am, Tuesday, 22'nd Apr 2025
When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessarily have to sacrifice growth for safety.
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
05:23am, Tuesday, 22'nd Apr 2025
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race?
02:31am, Tuesday, 22'nd Apr 2025
Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more than 10% last week after its US rival Eli Lilly & Co (NYSE: LLY) reported encouraging Phase 3 data for its oral weight-loss treatment. Lilly
